Michael Cannon, MD
Rheumatology · Virginia Beach, VANPI 1215925599
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $110,040 of the $145,271 with a category attached, or 75.7%. GSK accounts for 64.9% of it on its own, with 37 other manufacturers making up the rest. Among rheumatology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $184.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$94K
- Pfizer$32K
- Amgen$5K
- Johnson & Johnson$3K
- AbbVie$2K
- Sanofi$2K
- plus $7K from 32 others
What the payments were for
- Consulting fees$5,6604%
- Speaking & faculty fees$110,04076%
- Travel & lodging$11,7908%
- Food & beverage$17,70812%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 118 | $94,271 |
| Pfizer | 121 | $31,982 |
| Amgen(2 entities) | 126 | $5,052 |
| Johnson & Johnson(2 entities) | 35 | $3,055 |
| AbbVie | 77 | $2,274 |
| Sanofi | 6 | $1,752 |
| Lilly USA, LLC | 45 | $1,170 |
| Novartis | 45 | $1,014 |
| UCB, Inc. | 47 | $945 |
| Radius Health, Inc. | 18 | $487 |
| AstraZeneca(2 entities) | 17 | $436 |
| Aurinia Pharma U.S., Inc. | 11 | $409 |
| E.r. Squibb & Sons, L.L.C. | 18 | $331 |
| Boehringer Ingelheim | 11 | $282 |
| Mallinckrodt Hospital Products Inc. | 11 | $273 |
| Genentech USA, Inc. | 20 | $211 |
| Organon | 11 | $177 |
| Bristol Myers Squibb | 3 | $160 |
| ANI Pharmaceuticals, Inc. | 5 | $136 |
| Sobi, Inc | 5 | $128 |
| Bioventus LLC | 5 | $95 |
| Mallinckrodt Enterprises LLC | 3 | $80 |
| Sandoz | 4 | $72 |
| Octapharma USA, Inc. | 3 | $62 |
| Tersera Therapeutics LLC | 3 | $60 |
| Pharming Healthcare, Inc. | 3 | $58 |
| Fidia Pharma USA Inc. | 3 | $55 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Fresenius Kabi USA, LLC | 2 | $27 |
| Pacira Therapeutics, Inc. | 1 | $24 |
| Invivyd Inc | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $12 |
| Sebela Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$145,271 in reported general payments places this provider in the 95th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 12 | $661,775 |
| Humira(Cf) PenAdalimumab | 48 | $417,822 |
| RinvoqUpadacitinib | 25 | $199,605 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $155,100 |
| BenlystaBelimumab | 30 | $149,509 |
| Taltz AutoinjectorIxekizumab | 15 | $101,779 |
| EnbrelEtanercept | 12 | $88,329 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $68,681 |
| OtezlaApremilast | 12 | $60,456 |
| SaphneloAnifrolumab-Fnia | 11 | $55,776 |
| Actemra ActpenTocilizumab | 13 | $45,934 |
| ProliaDenosumab | 23 | $40,852 |
| Hydroxychloroquine Sulfate | 344 | $11,854 |
| MethotrexateMethotrexate Sodium | 249 | $8,212 |
| Celecoxib | 71 | $3,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq, Saphnelo | $436 | $717,55123 claims |
| AbbVieRinvoq | $2,274 | $199,60525 claims |
| AmgenEnbrel, Otezla, Prolia | $5,052 | $189,63747 claims |
| GSKBenlysta | $94,271 | $149,50930 claims |
| UCB, Inc.Cimzia (2 Pack) | $945 | $68,68112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Virginia Beach
- Tatiana KeckVirginia Beach$13K
- Janice SherwoodVirginia Beach$9K
- Peter LipskyCharlottesville$1.3M
- Kristi MizelleNewport News$1.1M
- Phillip KempfArlington$321K
- Sharukh ShroffDanville$216K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Phong NguyenReston$127K
- Chase CorreiaHampton$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.